You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVecuronium
Accession NumberDB01339
TypeSmall Molecule
GroupsApproved
DescriptionMonoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]
Structure
Thumb
Synonyms
Vecuronium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norcuron Inj 10mg/vialPowder, for solution10 mgIntravenousOrganon Canada Ltd Ltee1986-12-312009-08-04Canada
Vecuronium Bromide for InjectionPowder, for solution10.00 mgIntravenousHospira Healthcare Corporation2000-06-01Not applicableCanada
Vecuronium Bromide for InjectionPowder, for solution20.00 mgIntravenousHospira Healthcare Corporation2000-01-28Not applicableCanada
Vecuronium Bromide for InjectionPowder, for solution10 mgIntravenousPharmaceutical Partners Of Canada Inc2000-06-132008-02-15Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VecuroniumInjection, powder, lyophilized, for solution10 mg/10mLIntravenousSagent Pharmaceuticals2011-08-01Not applicableUs
VecuroniumInjection, powder, lyophilized, for solution20 mg/20mLIntravenousSagent Pharmaceuticals2011-08-01Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousGland Pharma Limited2016-06-30Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousHospira, Inc.1999-10-21Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousCardinal Health2000-08-01Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousAkorn Strides Llc2010-09-15Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousHospira, Inc.1999-10-21Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution10 mg/10mLIntravenousCardinal Health1999-08-25Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousSun Pharma Global FZE2014-12-15Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution10 mg/10mLIntravenousTeva Parenteral Medicines, Inc.2002-11-14Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousCardinal Health2009-07-21Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousGland Pharma Limited2016-06-30Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousSun Pharma Global FZE2014-12-15Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution20 mg/20mLIntravenousTeva Parenteral Medicines, Inc.2002-11-14Not applicableUs
Vecuronium BromideInjection, powder, lyophilized, for solution1 mg/mLIntravenousREMEDYREPACK INC.2015-06-23Not applicableUs
Vecuronium Bromide for InjectionInjection, powder, lyophilized, for solution1 mg/mLIntravenousSun Pharma Global Inc.2009-07-21Not applicableUs
Vecuronium Bromide for InjectionInjection, powder, lyophilized, for solution1 mg/mLIntravenousSun Pharma Global Inc.2009-07-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vecuronium bromide
50700-72-6
Thumb
  • InChI Key: VEPSYABRBFXYIB-PWXDFCLTSA-M
  • Monoisotopic Mass: 636.350171
  • Average Mass: 637.744
DBSALT001200
Categories
UNII5438723848
CAS number86029-43-8
WeightAverage: 557.8274
Monoisotopic: 557.431833322
Chemical FormulaC34H57N2O4
InChI KeyBGSZAXLLHYERSY-XQIGCQGXSA-N
InChI
InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-methylpiperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
Pharmacology
IndicationVecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
Structured Indications Not Available
PharmacodynamicsVecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
Mechanism of actionVecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
antagonist
HumanQ15822 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

100%

Route of eliminationFecal (40-75%) and renal (30% as unchanged drug and metabolites)
Half life51–80 minutes
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetaminophenThe serum concentration of Vecuronium can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinVecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Vecuronium.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Vecuronium.Approved
AfatinibThe serum concentration of Vecuronium can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Vecuronium can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Vecuronium can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Vecuronium can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Vecuronium can be increased when it is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alphacetylmethadol.Experimental, Illicit
AmantadineThe serum concentration of Vecuronium can be increased when it is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
Aminohippuric acidThe serum concentration of Vecuronium can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Vecuronium can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Vecuronium can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Vecuronium can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Vecuronium can be decreased when it is combined with Amprenavir.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
AmsacrineThe serum concentration of Vecuronium can be increased when it is combined with Amsacrine.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Vecuronium.Approved
annamycinannamycin may increase the respiratory depressant activities of Vecuronium.Investigational
AnvirzelVecuronium may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Vecuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Vecuronium.Approved
AstemizoleThe serum concentration of Vecuronium can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Vecuronium can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Vecuronium can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Vecuronium can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Vecuronium.Approved, Vet Approved
AzelastineThe serum concentration of Vecuronium can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Vecuronium can be increased when it is combined with Azithromycin.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Vecuronium.Approved
BenzocaineThe serum concentration of Vecuronium can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Vecuronium can be increased when it is combined with Bepridil.Approved, Withdrawn
BezitramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.Approved
BosutinibThe serum concentration of Vecuronium can be increased when it is combined with Bosutinib.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
Botulinum Toxin Type BVecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromocriptineThe serum concentration of Vecuronium can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
BuprenorphineThe serum concentration of Vecuronium can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Vecuronium can be increased when it is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Vecuronium can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Vecuronium can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Vecuronium can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Vecuronium can be increased when it is combined with Candesartan.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Vecuronium.Approved
CaptoprilThe serum concentration of Vecuronium can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Carfentanil.Illicit, Vet Approved
CarvedilolThe serum concentration of Vecuronium can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Vecuronium can be increased when it is combined with Caspofungin.Approved
ChloroquineThe serum concentration of Vecuronium can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe serum concentration of Vecuronium can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Vecuronium can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Vecuronium can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Vecuronium.Approved
CholesterolThe serum concentration of Vecuronium can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Vecuronium can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Vecuronium can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Vecuronium can be decreased when it is combined with Cimetidine.Approved
CimetropiumVecuronium may increase the anticholinergic activities of Cimetropium.Experimental
CiprofloxacinThe serum concentration of Vecuronium can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Vecuronium can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Vecuronium can be increased when it is combined with Clarithromycin.Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
ClofazimineThe serum concentration of Vecuronium can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Vecuronium can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Vecuronium can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Vecuronium can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Vecuronium can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Vecuronium can be increased when it is combined with Colforsin.Experimental
ColistimethateColistimethate may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Vecuronium can be increased when it is combined with Crizotinib.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.Approved
CyclophosphamideThe serum concentration of Vecuronium can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Vecuronium can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Vecuronium can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Vecuronium can be increased when it is combined with Dactinomycin.Approved
DantroleneDantrolene may increase the neuromuscular blocking activities of Vecuronium.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.Approved, Investigational
DasatinibThe serum concentration of Vecuronium can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Vecuronium can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Vecuronium.Approved
DesipramineThe serum concentration of Vecuronium can be increased when it is combined with Desipramine.Approved
DeslanosideVecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.Approved, Investigational
DexamethasoneThe serum concentration of Vecuronium can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dexetimide.Withdrawn
DextromethorphanThe serum concentration of Vecuronium can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Vecuronium can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.Approved
DigitoxinVecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinVecuronium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Vecuronium can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Vecuronium.Vet Approved
DiltiazemThe serum concentration of Vecuronium can be increased when it is combined with Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Vecuronium can be increased when it is combined with Dipyridamole.Approved
DonepezilThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Donepezil.Approved
DoxazosinThe serum concentration of Vecuronium can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Vecuronium can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Vecuronium can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Vecuronium is combined with DPDPE.Investigational
DronabinolVecuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Vecuronium can be increased when it is combined with Dronedarone.Approved
EchothiophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Edrophonium.Approved
ElbasvirThe serum concentration of Vecuronium can be increased when it is combined with Elbasvir.Approved
EluxadolineVecuronium may increase the constipating activities of Eluxadoline.Approved
EnalaprilThe serum concentration of Vecuronium can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Vecuronium can be increased when it is combined with Enzalutamide.Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Vecuronium.Approved
ErgonovineThe serum concentration of Vecuronium can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Vecuronium can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Vecuronium can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Vecuronium can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Vecuronium can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Vecuronium can be decreased when it is combined with Estrone.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Vecuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.Approved, Illicit
EtoposideThe serum concentration of Vecuronium can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Vecuronium can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Vecuronium can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Vecuronium can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.Approved
FexofenadineThe serum concentration of Vecuronium can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Vecuronium can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Vecuronium can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Vecuronium can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Vecuronium can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Vecuronium can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Vecuronium can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Vecuronium can be increased when it is combined with Fluvoxamine.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Vecuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Vecuronium.Approved
GefitinibThe serum concentration of Vecuronium can be increased when it is combined with Gefitinib.Approved, Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Vecuronium.Experimental
GenisteinThe serum concentration of Vecuronium can be increased when it is combined with Genistein.Investigational
GentamicinGentamicin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Vecuronium.Experimental
Ginkgo bilobaThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.Approved
GlyburideThe serum concentration of Vecuronium can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Vecuronium can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumVecuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Vecuronium can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Vecuronium can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Vecuronium can be increased when it is combined with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Vecuronium can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Vecuronium.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Vecuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Vecuronium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Vecuronium.Approved
IdelalisibThe serum concentration of Vecuronium can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Vecuronium can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Vecuronium can be increased when it is combined with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.Approved
IndinavirThe serum concentration of Vecuronium can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Vecuronium can be increased when it is combined with Indomethacin.Approved, Investigational
INNO-206INNO-206 may increase the respiratory depressant activities of Vecuronium.Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.Approved
IsavuconazoniumThe serum concentration of Vecuronium can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Vecuronium.Investigational
ItraconazoleThe serum concentration of Vecuronium can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vecuronium can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Vecuronium can be increased when it is combined with Ivermectin.Approved, Vet Approved
KanamycinKanamycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
KetamineThe serum concentration of Vecuronium can be increased when it is combined with Ketamine.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Vecuronium can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Vecuronium can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Vecuronium can be increased when it is combined with Lapatinib.Approved, Investigational
LevofloxacinThe serum concentration of Vecuronium can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Vecuronium can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Vecuronium can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Vecuronium can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Vecuronium can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Vecuronium can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neuromuscular blocking activities of Vecuronium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Vecuronium can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Vecuronium can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Vecuronium can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Vecuronium can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Vecuronium can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Vecuronium can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Vecuronium can be decreased when it is combined with Lumacaftor.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Vecuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Vecuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Vecuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
MalathionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Vecuronium can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Vecuronium can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.Approved
MefloquineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of Vecuronium can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MemantineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Vecuronium can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Vecuronium can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Vecuronium.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.Approved
MetixeneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.Approved
MetoprololThe serum concentration of Vecuronium can be increased when it is combined with Metoprolol.Approved, Investigational
MetrizamideMetrizamide may increase the respiratory depressant activities of Vecuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Vecuronium.Approved
MibefradilThe serum concentration of Vecuronium can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Vecuronium can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Vecuronium can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Vecuronium can be decreased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.Approved
MitomycinThe serum concentration of Vecuronium can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Vecuronium can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Vecuronium can be increased when it is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Vecuronium is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneVecuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.Approved
NaltrexoneThe serum concentration of Vecuronium can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Vecuronium can be increased when it is combined with Naringenin.Experimental
NeamineNeamine may increase the respiratory depressant activities of Vecuronium.Experimental
NefazodoneThe serum concentration of Vecuronium can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vecuronium can be decreased when it is combined with Nelfinavir.Approved
NeomycinNeomycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Vecuronium.Approved
NicardipineThe serum concentration of Vecuronium can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Vecuronium can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Vecuronium can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Vecuronium can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Vecuronium can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Vecuronium can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Vecuronium can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Vecuronium is combined with NVA237.Investigational
OmeprazoleThe serum concentration of Vecuronium can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpiumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.Approved
OuabainVecuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Vecuronium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
P-NitrophenolThe serum concentration of Vecuronium can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Vecuronium can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Vecuronium can be increased when it is combined with Palmitic Acid.Experimental
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.Approved
PantoprazoleThe serum concentration of Vecuronium can be increased when it is combined with Pantoprazole.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
ParoxetineThe serum concentration of Vecuronium can be increased when it is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Vecuronium.Approved
PerindoprilThe serum concentration of Vecuronium can be increased when it is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Vecuronium can be decreased when it is combined with Phenobarbital.Approved
PhysostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Physostigmine.Approved
PimozideThe serum concentration of Vecuronium can be increased when it is combined with Pimozide.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.Approved
PiperacillinPiperacillin may increase the neuromuscular blocking activities of Vecuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Vecuronium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Vecuronium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Piritramide.Investigational
Platelet Activating FactorThe serum concentration of Vecuronium can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinPlicamycin may increase the respiratory depressant activities of Vecuronium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Vecuronium.Approved
PonatinibThe serum concentration of Vecuronium can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Vecuronium can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideVecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Vecuronium.Approved, Investigational
PravastatinThe serum concentration of Vecuronium can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Vecuronium can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Vecuronium can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Vecuronium can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the neuromuscular blocking activities of Vecuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Vecuronium.Approved
ProgesteroneThe serum concentration of Vecuronium can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Vecuronium can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Vecuronium can be increased when it is combined with Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Propiverine.Investigational
PropranololThe serum concentration of Vecuronium can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Vecuronium can be increased when it is combined with Protriptyline.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Vecuronium.Experimental
PyridostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine.Approved
QuercetinThe serum concentration of Vecuronium can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Vecuronium can be increased when it is combined with Quinacrine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Vecuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Vecuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Vecuronium.Approved
RamosetronVecuronium may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Vecuronium can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Vecuronium can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Vecuronium can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Vecuronium can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.Approved
ReserpineThe serum concentration of Vecuronium can be decreased when it is combined with Reserpine.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Vecuronium.Approved
RifampicinThe serum concentration of Vecuronium can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Vecuronium can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Vecuronium can be decreased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
RolapitantThe serum concentration of Vecuronium can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Vecuronium can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.Approved, Investigational
SelegilineThe serum concentration of Vecuronium can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Vecuronium can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Vecuronium can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Vecuronium can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Vecuronium can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Vecuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Solifenacin.Approved
SorafenibThe serum concentration of Vecuronium can be increased when it is combined with Sorafenib.Approved, Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Vecuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
SpironolactoneThe serum concentration of Vecuronium can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Vecuronium can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Vecuronium can be increased when it is combined with Staurosporine.Experimental
StreptomycinStreptomycin may increase the respiratory depressant activities of Vecuronium.Approved, Vet Approved
StreptozocinThe serum concentration of Vecuronium can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Vecuronium can be increased when it is combined with Sulfinpyrazone.Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Vecuronium.Approved
SumatriptanThe serum concentration of Vecuronium can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Vecuronium can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Tacrine.Withdrawn
TacrolimusThe serum concentration of Vecuronium can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Vecuronium can be decreased when it is combined with Tamoxifen.Approved
TapentadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Vecuronium can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Vecuronium can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Vecuronium can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Vecuronium can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Vecuronium can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Vecuronium can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Vecuronium can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineTetracycline may increase the neuromuscular blocking activities of Vecuronium.Approved, Vet Approved
TicagrelorThe serum concentration of Vecuronium can be increased when it is combined with Ticagrelor.Approved
TiotropiumVecuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Vecuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Vecuronium.Approved, Investigational
TolvaptanThe serum concentration of Vecuronium can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.Approved, Investigational
TrazodoneThe serum concentration of Vecuronium can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Vecuronium.Approved, Vet Approved
TrifluoperazineThe serum concentration of Vecuronium can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Vecuronium can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium.Approved
TrimethoprimThe serum concentration of Vecuronium can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Vecuronium can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Vecuronium can be increased when it is combined with Troleandomycin.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Vecuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Vecuronium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Vecuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Vecuronium.Approved
VenlafaxineThe serum concentration of Vecuronium can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Vecuronium can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vecuronium can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vecuronium can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Vecuronium can be increased when it is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Vecuronium can be increased when it is combined with Zimelidine.Withdrawn
ZorubicinZorubicin may increase the respiratory depressant activities of Vecuronium.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Frans Herwig Jan Jansen, “Process to prepare pharmaceutical compositions containing vecuronium bromide and compositions produced thereby.” U.S. Patent US5681573, issued January, 1969.

US5681573
General ReferencesNot Available
External Links
ATC CodesM03AC03
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8913
Blood Brain Barrier+0.878
Caco-2 permeable+0.5457
P-glycoprotein substrateSubstrate0.77
P-glycoprotein inhibitor IInhibitor0.6962
P-glycoprotein inhibitor IIInhibitor0.6508
Renal organic cation transporterNon-inhibitor0.6862
CYP450 2C9 substrateNon-substrate0.8382
CYP450 2D6 substrateNon-substrate0.7638
CYP450 3A4 substrateSubstrate0.742
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9368
Ames testNon AMES toxic0.7499
CarcinogenicityNon-carcinogens0.9265
BiodegradationNot ready biodegradable0.8557
Rat acute toxicity2.6653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9021
hERG inhibition (predictor II)Non-inhibitor0.7784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Injection, powder, lyophilized, for solutionIntravenous10 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous20 mg/20mL
Powder, for solutionIntravenous10 mg
Powder, for solutionIntravenous10.00 mg
Powder, for solutionIntravenous20.00 mg
Prices
Unit descriptionCostUnit
Vecuronium 20 mg vial5.05USD vial
Vecuronium 10 mg vial3.64USD vial
Vecuronium 10 mg/10 ml syringe2.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.86e-05 mg/mLALOGPS
logP2.07ALOGPS
logP0.89ChemAxon
logS-7.5ALOGPS
pKa (Strongest Basic)9.65ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity169.31 m3·mol-1ChemAxon
Polarizability66.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • Cyclohexylamine
  • Piperidine
  • Acetate salt
  • Quaternary ammonium salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
  2. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030 ]
  3. Paul M, Fokt RM, Kindler CH, Dipp NC, Yost CS: Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor. Anesth Analg. 2002 Aug;95(2):362-7, table of contents. [PubMed:12145052 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7. [PubMed:9655875 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:08 / Updated on August 17, 2016 12:23